204 related articles for article (PubMed ID: 29689029)
1. REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY: A Multicenter Study.
Cernichiaro-Espinosa LA; Harper CA; Read SP; Wright LM; Scribbick FW; Young R; Negron CI; Rodríguez A; Berrocal AM
Retina; 2018 Jun; 38(6):1251-1255. PubMed ID: 29689029
[No Abstract] [Full Text] [Related]
2. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
3. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
[TBL] [Abstract][Full Text] [Related]
4. Globe size and bevacizumab treatment in retinopathy of prematurity: should we adjust the dose?
Connor AJ; Shafiq A
Eye (Lond); 2016 Nov; 30(11):1401-1403. PubMed ID: 27472209
[No Abstract] [Full Text] [Related]
5. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
[TBL] [Abstract][Full Text] [Related]
6. Management of Recurrent Retinopathy of Prematurity Following Anti-VEGF Injection.
Bhatt AR; Paul Chan RV; Reynolds JD; Wagner RS
J Pediatr Ophthalmol Strabismus; 2019 Mar; 56(2):68-70. PubMed ID: 30889257
[No Abstract] [Full Text] [Related]
7. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
8. How Does the Standard of Care Evolve? Anti-Vascular Endothelial Growth Factor Agents in Retinopathy of Prematurity Treatment as an Example.
Chiang MF
Ophthalmology; 2018 Oct; 125(10):1485-1487. PubMed ID: 30243329
[No Abstract] [Full Text] [Related]
9. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
10. The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab.
Alyamaç Sukgen E; Çömez A; Koçluk Y; Cevher S
Ophthalmologica; 2016; 236(3):139-147. PubMed ID: 27682852
[TBL] [Abstract][Full Text] [Related]
11. Retrolental Hemorrhage in Berger's Space After Intravitreal Bevacizumab Injection for Retinopathy of Prematurity.
Shah PR; Sachan A; Chandra P
J Pediatr Ophthalmol Strabismus; 2020 Oct; 57():e71-e73. PubMed ID: 33090229
[TBL] [Abstract][Full Text] [Related]
12. A new syringe adaptor for intravitreal injection of premature eye.
Kimura S; Tsukamoto M; Shiode Y; Hosogi M; Morizane Y
Retina; 2013 Apr; 33(4):889-90. PubMed ID: 23481457
[No Abstract] [Full Text] [Related]
13. Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity.
Chandra P; Kumawat D; Tewari R; Azimeera S
Indian J Ophthalmol; 2019 Jun; 67(6):967-969. PubMed ID: 31124535
[TBL] [Abstract][Full Text] [Related]
14. Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes.
Mintz-Hittner HA
J AAPOS; 2016 Dec; 20(6):478-480. PubMed ID: 27816750
[No Abstract] [Full Text] [Related]
15. Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1.
Kimyon S; Mete A
Ophthalmologica; 2018; 240(2):99-105. PubMed ID: 29920490
[TBL] [Abstract][Full Text] [Related]
16. Retinopathy of Prematurity Reactivated 28 Months after Injection of Ranibizumab.
Ji MH; Moshfeghi DM; Callaway NF; Bodnar Z; Schachar IH; Amorelli GM; Orazi L; Molle F; Lepore D
Ophthalmol Retina; 2019 Oct; 3(10):913-915. PubMed ID: 31474514
[No Abstract] [Full Text] [Related]
17. Late-onset tractional fibrovascular proliferation post-intravitreal bevacizumab following treatment of retinopathy of prematurity.
Agarwal-Sinha S; Guevara JG; Amin SM
Can J Ophthalmol; 2018 Jun; 53(3):e99-e103. PubMed ID: 29784188
[No Abstract] [Full Text] [Related]
18. Efficacy of Primary Intravitreal Ranibizumab for Retinopathy of Prematurity in China.
Feng J; Qian J; Jiang Y; Zhao M; Liang J; Yin H; Chen Y; Yu W; Li X
Ophthalmology; 2017 Mar; 124(3):408-409. PubMed ID: 27914833
[No Abstract] [Full Text] [Related]
19. Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity.
Li XJ; Yang XP; Sun S; Lyu XB; Jia H
Chin Med J (Engl); 2016 Dec; 129(23):2879-2881. PubMed ID: 27901006
[No Abstract] [Full Text] [Related]
20. Bilateral Total Cataract After Intravitreal Bevacizumab Injection in Aggressive Posterior Retinopathy of Prematurity.
Khokhar S; Chandra P; Gupta Y; Kumawat D; Dhull C
J Pediatr Ophthalmol Strabismus; 2019 Mar; 56():e28-e30. PubMed ID: 30907975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
